CervoMed Joins Russell 2000® and 3000® Indexes

BOSTON, June 24, 2024-- CervoMed Inc. (NASDAQ: CRVO), a clinical-stage company dedicated to developing treatments for age-related neurological disorders, has announced its anticipated inclusion in the Russell 2000® and Russell 3000® Indexes following the 2024 Russell U.S. Indexes annual reconstitution. This inclusion will be effective as soon as U.S. equity markets open on Monday, July 1, 2024, as confirmed by the final preliminary list of 2024 additions posted on the FTSE Russell website on June 21, 2024.

John Alam, MD, Chief Executive Officer of CervoMed, expressed that being added to these significant Russell Indexes is a vital milestone for the company. He noted that this reflects the growing market recognition of CervoMed's progress in advancing neflamapimod, which is being developed as a potential first-to-market treatment for patients with Dementia with Lewy Bodies (DLB). Alam anticipates that this inclusion will increase awareness of CervoMed as they approach the release of topline results from the Phase 2b RewinD-LB trial in December 2024.

The annual reconstitution of the Russell U.S. Indexes identifies the 4,000 largest U.S. stocks as of April 30th, ranked by total market capitalization. Being part of the U.S. all-cap Russell 3000® Index also means automatic inclusion in either the large-cap Russell 1000® Index or the small-cap Russell 2000® Index, along with the relevant growth and value style indexes. FTSE Russell determines the membership for its indexes based on market-capitalization rankings and style attributes. These indexes are extensively used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies.

CervoMed Inc. is focused on developing neflamapimod, an investigational, orally-administered small molecule that penetrates the brain and inhibits p38MAP kinase alpha. This drug has the potential to treat synaptic dysfunction, a reversible aspect of the neurodegenerative process underlying DLB and other major neurological disorders. Neflamapimod is currently undergoing evaluation in a Phase 2b study involving patients with DLB.

FTSE Russell, a leading global provider of benchmarking, analytics, and data solutions, offers precise market insights to investors. Their comprehensive range of reliable and accurate indexes equips investors globally with the necessary tools to measure and benchmark markets across various asset classes, styles, or strategies. FTSE Russell indexes are widely adopted by institutional and retail investors for benchmarking investment performance and creating exchange-traded funds (ETFs), structured products, and index-based derivatives.

For over three decades, FTSE Russell's index expertise and products have been preferred by leading asset owners, asset managers, ETF providers, and investment banks. The company is committed to maintaining the highest industry standards in index design and governance, employing a transparent, rules-based methodology informed by independent committees of leading market participants. FTSE Russell adheres to the IOSCO Principles and its Statement of Compliance has received independent assurance. The firm's index innovation is driven by client needs and customer partnerships, enabling continual enhancement of their offerings.

FTSE Russell is wholly owned by the London Stock Exchange Group and continues to expand the breadth, depth, and reach of its index offerings, driven by client needs and collaboration.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!